Drug Trial Radar · NCT06575478
Evaluation of Fuling Yunhua Granules and Dihuang Baoyuan Granules in Drug Naive Type 2 Diabetes Patients
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
95
Actual
Start
Jul 31, 2024
Primary completion
Jan 27, 2025
Study completion Jan 27, 2025
Sponsor
- Lead sponsor
- Beijing Supreme Life Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Peking University People's Hospital
- First posted
- Aug 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this investigator-initiated clinical trial is to investigate the efficacy and safety of sequential therapy of Fuling Yunhua Granules (prescription A) and Dihuang Baoyuan Granule (prescription B) in the treatment of type 2 diabetes patients with poor glycemic control after diet and exercise intervention.
Conditions
- Diabetes Mellitus, Type 2
- Diabetes
- Type2diabetes
Interventions
Fuling Yunhua GranulesDrug
Fuling Yunhua Granules
Dihuang Baoyuan GranulesDrug
Dihuang Baoyuan Granules
Fuling Yunhua Granules matched placebo/Dihuang Baoyuan Granules matched placeboDrug
Fuling Yunhua Granules placebo/Dihuang Baoyuan Granules placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c Concentrations (%) From BaselineTime frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.